Breast Cancer: An Overview

PharmaTutor (November- 2013)

Received On: 08/10/2013; Accepted On: 02/11/2013; Published On: 25/11/2013

Author:
Amardeep Sharma
Rathi Orthopaedic & Research Centre,
Ahmedabad, Gujarat, India
amardeep.sharma54@gmail.com

ABSTRACT: The knowledge of breast cancer development and progression has grown in recent years and relatively development of novel therapeutic strategies, but for cancer mortalities in women breast cancer stands at 2^nd position as cause.

In U.S. Approximately 39970 women & 450 men in the U.S. will be diagnosed from the disease in 2011. Breast cancer is a hormone dependent disease. Breast cancer occurs when breast epithelial cells grows in abnormal way. HER2/neu, ER, PR, BRCA1, BRCA2 are the well known influencing factors responsible for breast cancer initiation. The major issues that limit the currently available breast cancer treatment are high cost, poor availability and resistance to chemotherapeutic agents. To overcome this problem researchers are working on several novel approaches i.e. “Novel drug targets & Novel target therapies”.

Since from past few years, mammogram is playing a huge role for decreasing incidence rate in developed countries. Breast cancer is adversely affecting the “quality of life” of patients and its impact has been increasing on the Social capital, population structure and economic growth. Need for novel anti breast cancer agent and novel early diagnosis technique is necessary to combat one of the most serious crises facing Human development.

How to cite this article: Sharma A, Breast Cancer: An Overview, PharmaTutor, 2013, 1(1), 29-38

[ABSTRACT WITH CITATION] [VIEW AS HTML]

REFERENCES:
1. Osteen, R. Breast Cancer. In: Lenhard RE, Osteen RT, Gansler R, eds. Clinical Oncology. Atlanta, GA: American Cancer Society; 2001:251–268.
2. Dennis L. Kasper, Eugene Braunwald, Anthony S. fauci et al. Harrisson’s Principle of Internal Medicine. McGraw Hill, Medical Publishing Division. 16Th Edition, 516-517.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010. Available from: globocan.iarc.fr
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66–71.
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792
6. Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv 1993; 18, 95–113.
7. Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis.Am J Hum Genet 1997; 61, 1254–1260.
8. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep 2004;5:772–776.
9. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25:5912–5919.
10. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007;16(Spec No. 1):R60–R66.
11. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet2007;39:165–167.
12. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40:17–22.
13. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792.
14. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science1994;265:2088–2090.
15. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer1998;83:2335–2345.
16. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011–2017.
17. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171–182.
18. worldwidebreastcancer.com/risks/breast-cancer-world-statistics/
19. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-234.
20. Reid A, Vidal L, shaw H, de Bono: Dual inhibition of ErbB1(EGFR/HER1) and ErbB2(HER2/neu), Eurj cancer 2007, 43, 481-489.
21. Geyer CE, Forster J , Lind quist D, et al. Lapatinib plus capecita- bine for HER-2 positive advanced breast cancer. N Engl J Med 2006, 355, 2733-2743.
22. Cristofanilli M, boussen H, Baselga J, et al. A Phase ii combination study of lapatinib and paclitaxel as a neoadjuvent therapy in patients with newly diagnosed inflammantory breast cancer (IBC) san antonio Breast cancer symposium 2006, Abstract Nr.1, General session.
23. Cristofanilli M, Krisnamurthy S, Guerr L, A nonreplicating adeno-viral vector that contains the wild- type p53 transgenes combined with chemotherapy for primary breast cancer: Safety, efficacy, and biologic activity of a novel gene therapy approach. Cancer 2006, 107, 935-944.
24. Appels Nm, Beijnen JH; Schellens JH. Development of farnesyl transferase inhibitor: a review. Oncologist 2005, 10, 565-578.
25. Gligorav J, Azria D, Namer M et al: Novel therapeutic strategies combining antihormonal & biological targeted therapies in breast cancer: Focus on clinical trials and perspectives. Crit Rev. Oncol Hematol 2007, 64, 115-128.
26. Yang CH, Gonzalez-Angulo AM, Reuben JM, et al: Bortezomid(velcade) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann oncol 2006, 17; 813-817.
27. Engel RH, Brown JA, Van Roenn JH et al; A Phase ii study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer invest 2007, 25, 733-737.
28. Cardoso F, Durbecq V, Laes JF, et al; Bortezomib (PS-341, Velcade) increase the efficacy of Trastuzumab(Herceptin) in HER-2 positive breast cancer cells in a synergistic manner. Mol. Cancer ther. 2006, 5; 3042-3051.
29. Cobleigh MA, Langmuir VK, Sledge GW et al: A Phase i/ii dose- escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin oncol 2003, 30,: 117-124.
30. Sledge G, Miller K, Novotny W, et al;: A Phase ii trial of single – agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer (Abstract 5c) proc Am soc clin oncol 2000, 19:3a.
31. Madi S, D’Andrea G, Norton L, et al. APhase I study of cetuzumab/ pacclitaxel in patients with advanced- stage breast cancer. Clin breast cancer 2006, 7,: 270-277.
32. Guix M, Granja Nde, Meszoely et al. Short preoperative opration with erlotinib inhibit tumor cell proliferation in hormone receptor positive breast cancer. J Clin oncol, 2008, 26, 897-900.
33. Rita Nahta, Dihua Yu, Mien- Chie Hung et al; Mechanism of disease understanding resistance to HER-2 targeted therapy in human breast cancer. Nature practice oncology, may 2006, 3(No.5), 275.
34. Dan Peer, Jeffrey M. KarP, SeungPyo Hong, et al. Nanocarriers as an emerging platform for cancer therapy.nature nanotechnology. DECEMBER 2007, 2, 755.
35. Osborne C., Wilson P., tripathy D. oncogenes and tumor suppressor genes in breast cancer. Potential diagnostic and therapeutic applications. The oncologist. 2004,9, 361-377.
36. Ganesh N Sharma, Rahul dave, Jyotsana sanadya et al. Various types and management of breast cancer: An overview, J. Adv. Pharm. Tech. Res. Apr-jun,2010 1(2), 119-121.
37. Jin-Hui W., Xin- Yuan L. targeting strategies in cancer gene therapy. ACTA Biochimica and biophysica sinica. 2003; 35, 311-316.
38. Claus M Schlotter,Ulf Vogt, Heike Allgayer and Burkhard Brandt. Molecular targeted therapies for breast cancer treatment. BioMed Central Ltd., Breast Cancer Research 2008, 10:211(doi:10.1186/bcr2112).

Search

Breast Cancer: An Overview

RECOMMENDED POSTS

Subscribe with us

Jobs by Category